Empathy, affection and sociability enhancement
Empathy, affection, and sociability enhancement can be described as the experience of a mind state which is dominated by intense feelings of compassion, talkativeness, and happiness. The experience of this effect creates a wide range of subjective changes to a person's perception of their feelings towards other people and themselves. These are described and documented in the list below:
- Increased sociability and the feeling that communication comes easier and more naturally.
- Increased urge to communicate or express one's affectionate feelings towards others, even if they happen to be strangers.
- Increased feelings of empathy, love, and connection with others.
- Increased motivation to resolve social conflicts and improve interpersonal relationships.
- Decreased negative emotions and mental states such as stress, anxiety, and fear.
- Decreased insecurity, defensiveness, and fear of emotional injury or rejection from others.
- Decreased irritability, aggression, anger, and jealousy.
Empathy, affection, and sociability enhancement is often accompanied by other coinciding effects such as stimulation, personal bias suppression, motivation enhancement, and anxiety suppression. It is most commonly induced under the influence of moderate dosages of entactogenic compounds such as MDMA, 4-FA, and 2C-B. However, it can also subtly occur to a much lesser extent under the influence of GABAergic depressants, and certain stimulants.
Compounds within our psychoactive substance index which may cause this effect include:
Anecdotal reports which describe this effect within our experience index include:
- Experience: 105mg Ephenidine - An Intense Emotional Experience
- Experience: 15mg 2C-B (oral) - A pleasant low-dose evening with Nexus
- Experience: 15mg 4F-EPH - Untitled
- Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
- Experience:0.75g MDMA - Possibly some MDA through metabolisation?
- Experience:1000 Morning Glory seeds - Rediscovering the Self
- Experience:12 mg AMT - Nicely Surprised
- Experience:150mg MDMA + 20mg 2C-B - I designed it this way myself
- Experience:25mg - A labyrinth of organs and a storybook walk
- Experience:3.5g psilocybe cubensis - Relinquishing of Material Chains/Fear and Desolation
- Experience:300µg - Togetherness and the Silent Dusk
- Experience:30mg (smoked) DMT - The Monolith
- Experience:30mg - Psychostimulant egodeath
- Experience:3g mimosa / 2g syrian rue - I was the Universe's prophet
- Experience:4-AcO-DMT -- Recklessness rewarded
- Experience:42 mg TMA-6: Pure Bliss
- Experience:60mg 4-AcO-DMT Nonstop Quasi-Orgasmic Objectless Euphoria
- Experience:75mg 3-FMA - Perfect Blend of Euphoria and Functionality
- Experience:A combination of DOC, 5-MAPB, 5-MeO-DMT, ETH-LAD, Cannabis, Pentedrone
- Experience:A night with Ethylphenidate
- Experience:BK-2C-B - Various experiences
- Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)
- Experience:Unknown dosage / 3 tabs - Ego death and a total break through in the snow
- Responsible use
- Subjective effects index
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Tanaka, E., Kamata, T., Katagi, M., Tsuchihashi, H., & Honda, K. (2006). A fatal poisoning with 5-methoxy-N, N-diisopropyltryptamine, Foxy. Forensic science international, 163(1-2), 152-154. https://doi.org/10.1016/j.forsciint.2005.11.026
- Shulgin, A. T., & Carter, M. F. (1980). N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Communications in psychopharmacology, 4(5), 363-369. https://www.ncbi.nlm.nih.gov/pubmed/6949674
- Muller, A. A. (2004). New drugs of abuse update: Foxy Methoxy. Journal of Emergency Nursing, 30(5), 507-508. https://doi.org/10.1016/j.jen.2004.07.037
- Meatherall, R., & Sharma, P. (2003). Foxy, a designer tryptamine hallucinogen. Journal of analytical toxicology, 27(5), 313-317. http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=F3773EF1876BD69CAF408DA77CCBF8EF?doi=10.1.1.689.2033&rep=rep1&type=pdf